Bristol-Myers to acquire Adnexus for $430M

Bristol-Myers Squibb Co. said it will purchase biotech firm Adnexus Therapeutics for $430 million and up to $75 million in additional conditional payments, to help develop its class of drugs, called Adnectins, and expand the firm's investment in biologics. "We feel biologics will be a cornerstone of our future growth," a Bristol-Myers executive said.

View Full Article in:

Boston Globe (tiered subscription model), The · San Diego Union-Tribune

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Corporate Counsel - Regulatory Law
Regeneron
Tarrytown, NY
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC
Senior Attorney
Blue Cross Blue Shield of Louisiana
Baton Rouge, LA
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
Chief Financial Officer
Health Alliance Plan of Michigan
Southfield, MI